Skip to main content

Hemex attracts Swiss investors

| News

Hemex attracts Swiss investors

11.02.2021

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The biotech incubator will use the funds to accelerate its global expansion.

Hemex, a Basel Area-based venture capitalist and incubator for biotech startups, has reported raising “a substantial amount” in an oversubscribed Series C financing round. According to a press release, the capital contribution was raised exclusively from a group of Swiss private investors.

Now, Hemex plans to use this money to hire “world-class talent” and accelerate its global expansion. The company wants to “invest in carefully selected startups” and deliver on its promise of “changing the future of healthcare”.

“We anticipate another year of strong growth for healthcare, both domestically and on a global level,” said Hemex CEO Pascal Winnen in the press release. “This vote of confidence for our business model from a group of successful entrepreneurs confirms that Hemex is on the right track for substantial future success.”

Hemex’s partners include the investment and innovation promotion agency Basel Area Business & Innovation and its DayOne Accelerator. Its portfolio includes Opterion Health AG, which announced at the end of January that it would be moving from the canton of Obwalden to the co-working space The 5th Floor in Muttenz. Basel Area Business & Innovation is providing support for the relocation.

In addition, Hemex has invested in Scailyte, a company based at the Novartis Campus of the Switzerland Innovation Park Basel Area. Support has also been provided to Resistell based in Muttenz, which claims to have made the world’s fastest antibiogram, and Basel cancer diagnostics expert Artidis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.